Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11265829 | 0.83 | RAB9A (0.57) | RAB9AALDH1A1GAASMN1; SMN2HTT | |
| SCHEMBL23077935 | 0.80 | HDAC8 (0.57) | RAB9AALDH1A1GAASMN1; SMN2HTT | |
| SCHEMBL8352671 | 0.79 | KMT2A (0.58) | RAB9AALDH1A1GAASMN1; SMN2HTT | |
| SCHEMBL9377954 | 0.79 | GAA (0.54) | RAB9AALDH1A1GAASMN1; SMN2HTT | |
| SCHEMBL721637 | 0.77 | CYP2C19 (0.57) | RAB9AALDH1A1GAASMN1; SMN2HTT | |
| SCHEMBL28668774 | 0.77 | GAA (0.79) | RAB9AALDH1A1GAASMN1; SMN2HTT | |
| SCHEMBL9370124 | 0.76 | RAB9A (0.55) | RAB9AALDH1A1GAASMN1; SMN2HTT | |
| SCHEMBL20395222 | 0.75 | CYP2C19 (0.59) | RAB9AALDH1A1GAASMN1; SMN2HTT | |
| SCHEMBL499117 | 0.75 | CYP2C19 (0.64) | RAB9AALDH1A1GAASMN1; SMN2HTT | |
| SCHEMBL17117492 | 0.75 | NPC1 (0.75) | RAB9AALDH1A1GAASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420698-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120035257-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2012-02-09 | — | — | US | disclosed |
| US-20110287535-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-8026280-B2 | For therapy of cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy. | ERRANT GENE THERAPEUTICS, LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-7902259-B2 | with zinc-binding activities; 5-phenyl-2,4,-pentadienoyl hydroxamic acid; gene expression inhibitor; anticarcinogenic, antitumor, antiprotozoa agent, viricide; hematological disorders, hemoglobinopathies, genetic related metabolic disorders, cystic fibrosis | ERRANT GENE THERAPEUTICS, LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7858664-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-7842727-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100234455-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2010-09-16 | — | — | US | disclosed |
| WO-2008011074-A2 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
| US-7312247-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1817020-A2 | HISTONE DEACETYLASE INHIBITORS | Errant Gene Therapeutics, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | ERRANT GENE THERAPEUTICS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20060160902-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2006-07-20 | — | — | US | disclosed |
| WO-2006052916-A2 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050171208-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC, A DELAWARE LIMITED LIABILITY CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-20050107348-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC, A DELAWARE LIMITED LIABILITY CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20030125306-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035257-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC11, HDAC9 | RAB9A 4017/4885ALDH1A1 374/4885GAA 130/4885 |
| US-20050171208-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | RAB9A 4017/4885ALDH1A1 374/4885GAA 130/4885 |
| US-20030125306-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | RAB9A 4026/4885ALDH1A1 474/4885GAA 127/4885 |
| US-20050107348-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | RAB9A 4017/4885ALDH1A1 374/4885GAA 130/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | RAB9A 3585/4885ALDH1A1 269/4885GAA 114/4885 |
| US-20100234455-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | RAB9A 3807/4885ALDH1A1 1607/4885GAA 3118/4885 |
| US-20060160902-A1 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC11 | RAB9A 3807/4885ALDH1A1 1607/4885GAA 3118/4885 |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC6, HDAC5 | RAB9A 3788/4885ALDH1A1 778/4885GAA 83/4885 |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | HDAC5, HDAC1, ZNF277 | RAB9A 4058/4885ALDH1A1 370/4885GAA 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.